Application of Caerin 1.1/1.9 combined with anti-CD47 antibody in preparing drug for treating melanoma
The present invention belongs to the field of biotechnology, and particularly relates to an application of Caerin 1.1/1.9 combined with an anti-CD47 antibody in preparing a drug for treating melanoma. In the present invention, an amino acid sequence of the Caerin 1.1 is shown in SEQ ID NO.1; and an amino acid sequence of the Caerin 1.9 is shown in SEQ ID NO.2. The Caerin 1.1/1.9 of the present invention may promote B16 cells to highly express CD47 while leading to apoptosis of the B16 cells, promote macrophages to phagocytose tumor cells in the presence of anti-CD47 antibodies, improve the curative effect of the Caerin 1.1/1.9, which is also superior to that of a single anti-CD47 antibody, and lays a foundation for expanding the application of CD47 inhibition/blocking drugs.
1 . A method of treating melanoma in a subject, comprising:
administering to the subject Caerin 1.1/1.9 and an anti-CD47 antibody clone MIAP301;
wherein a mass ratio of the Caerin 1.1/1.9 to the anti-CD47 antibody is 3: (10-25);
the Caerin 1.1/1.9 consists of Caerin 1.1 and Caerin 1.9 according to a mass ratio of 1:1;
an amino acid sequence of the Caerin 1.1 is shown in SEQ ID NO.1; and an amino acid sequence of the Caerin 1.9 is shown in SEQ ID NO.2.
2 . The method according to claim 1 , wherein the drug further comprises a pharmaceutically acceptable carrier.
3 . A method of inducing melanoma cells B16 to highly express CD47, comprising:
treating the melanoma cells B16 with Caerin 1.1/1.9;
wherein the Caerin 1.1/1.9 consists of Caerin 1.1 and Caerin 1.9 according to a mass ratio of 1:1; an amino acid sequence of the Caerin 1.1 is shown in SEQ ID NO.1; and an amino acid sequence of the Caerin 1.9 is shown in SEQ ID NO.2.
4 . The method according to claim 1 , wherein the step of administering Caerin 1.1/1.9 and the anti-CD47 antibody clone MIAP301 results in repolarization of tumor-infiltrating macrophages from an M2 type to an M1 type.
5 . The method according to claim 4 , wherein the step of administering Caerin 1.1/1.9 and the anti-CD47 antibody clone MIAP301 results in increased interleukin-12 secretion and decreased interleukin-10 secretion.
6 . The method according to claim 5 , wherein the step of administering Caerin 1.1/1.9 and the anti-CD47 antibody clone MIAP301 results in increased expression of CD47 on melanoma cells.